

RSL/AH

22nd August 1988.

Dr. R.J. Moore,
Department of Health and Social Security,
Alexander Fleming House,
Elephant and Castle,
London SE1 6BY.

Dear Roger,

Non HIV-tested Plasma Stock, BPL, Elstree

Material:

Fresh Frozen	50.7 tonnes	(85 pallets)
Time Expired	126. tonnes	(126 pallets)

Storage charges:

June 1986 - March 1988	£40,512
April 1988 - August 1988	£ 9,980

to-date Total £50,492

The history of this plasma is well known to you and DHSS. At present BPL is striving to achieve work-up of production to meet targets, and there is no leeway between budget and demands for establishment within this financial year to facilitate these operational objectives.

The cost of keeping the plasma in question for a further seven months will be £13,600, i.e. the cost of two full-time operatives.

A decision is needed urgently on the fate of this plasma. I have indicated that, on scientific grounds, I have no objection to making Albumin Solution (market value £5.35 million). However, I now believe that the implications of Regulatory requirements, the Consumer Protection Act and the attempted litigation by certain Haemophilia groups make it highly improbable that this plasma will ever receive approval for processing to therapeutic product. In addition, once BPL becomes a licensed manufacturer, I assume that we will be unable to use untested plasma for therapeutic products, in line with standing recommendations from the Licensing Authority to other licensed manufacturers.

May I propose DHSS signify their intentions to CBLA by the end of August?

Yours sincerely,

R. S. LANE.

c.c. Chairman, CBLA
Chief Executive CBLA
Dr. E.L. Harris, DHSS